Company Encyclopedia
View More
name
NeuroPace
NPCE.US
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
1.400 T
NPCE.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking67/170
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-169.27%E
    • Profit Margin-25.28%E
    • Gross Margin77.39%A
  • Growth ScoreB
    • Revenue YoY24.08%A
    • Net Profit YoY14.61%C
    • Total Assets YoY11.37%B
    • Net Assets YoY88.52%A
  • Cash ScoreC
    • Cash Flow Margin-395.50%D
    • OCF YoY24.08%A
  • Operating ScoreA
    • Turnover0.93A
  • Debt ScoreE
    • Gearing Ratio82.73%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NeuroPace’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating

    Analyst Yi Chen from H.C. Wainwright has reiterated a Buy rating on NeuroPace, maintaining a price target of $18.00. This decision is based on the company's strong financial performance, including a 29.9% year-over-year revenue increase in Q3 2025 and a lower-than-expected net loss. Strategic initiatives, such as terminating the DIXI distribution agreement, are expected to enhance focus on the responsive neurostimulation system, projected to grow by 20% in 2026. Lake Street also issued a Buy rating with a $20.00 price target.

    Tip Ranks·
    US
    NPCE
    +6.30%
    Tip Ranks·
    US
    NPCE
    +6.30%

    NeuroPace (NPCE): Forecasts Point to Profitability Within Three Years, Reinforcing Bullish Growth Narratives

    NeuroPace (NPCE) is projected to achieve profitability within three years, with revenue growth expected at 14.9% annually and earnings rising at 64.52% per year. Despite current unprofitability, losses have decreased by 2.2% annually over the past five years. The company's shares trade at a 31.8% discount to their DCF fair value, presenting a potential opportunity for investors. However, analysts caution that margin pressures from product mix changes and reliance on new offerings could impact financial results. Overall, NeuroPace's growth strategy involves aggressive market expansion and innovation.

    Simplywall·
    US
    NPCE
    +6.30%
    Simplywall·
    US
    NPCE
    +6.30%

    NeuroPace, Inc. Reports Record Revenue and Growth

    NeuroPace, Inc. reported record revenue of $27.4 million for Q3 2025, a 30% increase year-over-year, driven by RNS initial implants. The company achieved positive adjusted EBITDA for the first time, reflecting strong scalability. Full-year revenue guidance was raised to $97-$98 million, with gross margins expected at 76%-77%. Despite a net loss of $3.5 million, an improvement from last year, NeuroPace remains optimistic about future growth, targeting a minimum of 20% growth in its core RNS business. The company is committed to expanding its product offerings and addressing new market segments.

    Tip Ranks·
    US
    NPCE
    +6.30%
    Tip Ranks·
    US
    NPCE
    +6.30%

    Cantor Fitzgerald Remains a Buy on NeuroPace (NPCE)

    Osborn covers the Healthcare sector, focusing on stocks such as Organogenesis Holdings, NeuroPace, and Cerus. According to TipRanks, Osborn has an average return of -6.5% and a 28.81% success rate on recommended stocks. In addition to Cantor Fitzgerald, NeuroPace also received a Buy from Lake Street’s Frank Takkinen in a report issued today. However, on October 30, TR | OpenAI – 4o reiterated a Hold rating on NeuroPace (NASDAQ: NPCE).

    Tip Ranks·
    US
    NPCE
    +6.30%
    Tip Ranks·
    US
    NPCE
    +6.30%

    J.P. Morgan Reaffirms Their Buy Rating on NeuroPace (NPCE)

    According to TipRanks, K Patel is ranked #9119 out of 10072 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for NeuroPace with a $16.86 average price target, implying a 79.36% upside from current levels. In a report released on November 3, Lake Street also maintained a Buy rating on the stock with a $20.00 price target.

    Tip Ranks·
    US
    NPCE
    +6.30%
    Tip Ranks·
    US
    NPCE
    +6.30%